PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
12824957-2	2003	Therefore, we evaluated the clinical tolerance and biological effects of immunotherapy with the synthetic immunomodulator Murabutide in 9 treatment-naive HIV-1 patients presenting with CD4+ lymphocyte counts >500 cells/mm3 and plasma viral loads <30.000 copies/ml.	murabutide	122-132	CD4 molecule	Homo sapiens	185-188
12716777-7	2003	Some of these clinical changes were maintained even up to 12 weeks after murabutide administration, and were accompanied by an increased ability to mount cellular responses to active immunization with a recall antigen, and by a significant increase in the percentage of patients presenting positive lymphoproliferative responses to the viral antigen gp160.	murabutide	73-83	glutamyl aminopeptidase	Homo sapiens	350-355
12131566-2	2002	The safe synthetic immunomodulator Murabutide (ISTAC Biotechnology, Lille, France) has been found to regulate the function of antigen-presenting cells and to selectively activate CD4 lymphocytes leading to dramatic suppression of HIV replication, in vitro.	murabutide	35-45	CD4 molecule	Homo sapiens	179-182
11529939-4	2001	We found that Murabutide triggers immunophenotypic changes as upon treatment, iDCs up-regulate the surface expression of the major histocompatibility complex type II molecule human leucocyte antigen-DR, the co-stimulatory molecules CD80, CD86 and CD40 and the differentiation marker CD83, and down-regulate the expression of the mannose receptor.	murabutide	14-24	CD86 molecule	Homo sapiens	238-242
11576459-2	2001	Murabutide (N-acetyl muramyl-L-alanyl-D-glutamine-O-n-butyl-ester) (ISTAC Biotechnology, Lille, France) is a safe synthetic and clinically acceptable immunomodulator that enhances the biologic activities of IFN-alpha in different experimental models.	murabutide	0-10	interferon alpha 1	Homo sapiens	207-216
11576459-3	2001	We evaluated in healthy human volunteers tolerance of the coadministration of Murabutide with increasing doses of IFN-alpha.	murabutide	78-88	interferon alpha 1	Homo sapiens	114-123
11529939-4	2001	We found that Murabutide triggers immunophenotypic changes as upon treatment, iDCs up-regulate the surface expression of the major histocompatibility complex type II molecule human leucocyte antigen-DR, the co-stimulatory molecules CD80, CD86 and CD40 and the differentiation marker CD83, and down-regulate the expression of the mannose receptor.	murabutide	14-24	CD40 molecule	Homo sapiens	247-251
11529939-4	2001	We found that Murabutide triggers immunophenotypic changes as upon treatment, iDCs up-regulate the surface expression of the major histocompatibility complex type II molecule human leucocyte antigen-DR, the co-stimulatory molecules CD80, CD86 and CD40 and the differentiation marker CD83, and down-regulate the expression of the mannose receptor.	murabutide	14-24	CD80 molecule	Homo sapiens	232-236
11529939-4	2001	We found that Murabutide triggers immunophenotypic changes as upon treatment, iDCs up-regulate the surface expression of the major histocompatibility complex type II molecule human leucocyte antigen-DR, the co-stimulatory molecules CD80, CD86 and CD40 and the differentiation marker CD83, and down-regulate the expression of the mannose receptor.	murabutide	14-24	CD83 molecule	Homo sapiens	283-287
11529939-8	2001	Furthermore, in the presence of Murabutide, DCs transiently increased the release of macrophage inhibitory protein-1 beta, tumour necrosis factor-alpha and interleukin-10, whereas the enhanced production of macrophage-colony stimulating factor was sustained over the 3-day period analysed.	murabutide	32-42	interleukin 10	Homo sapiens	156-170
11435574-2	2001	The present study was designed to profile the activity of Murabutide on CD8-depleted phytohemagglutinin-activated lymphocytes from HIV-1-infected subjects and on the outcome of HIV-1 infection in severe combined immunodeficiency mice reconstituted with human peripheral blood leukocytes (hu-PBL-SCID mice).	murabutide	58-68	CD8a molecule	Homo sapiens	72-75
11435574-3	2001	Maintaining cultures of CD8-depleted blasts from 36 patients in the presence of Murabutide produced dramatically reduced levels of viral p24 protein in the supernatants.	murabutide	80-90	CD8a molecule	Homo sapiens	24-27
11435574-3	2001	Maintaining cultures of CD8-depleted blasts from 36 patients in the presence of Murabutide produced dramatically reduced levels of viral p24 protein in the supernatants.	murabutide	80-90	transmembrane p24 trafficking protein 2	Homo sapiens	137-140
11435574-5	2001	Moreover, c-myc mRNA expression was down-regulated in Murabutide-treated cells, suggesting potential interference of the immunomodulator with the nuclear transport of viral preintegration complexes.	murabutide	54-64	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	10-15
11449348-0	2001	Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.	murabutide	28-38	mitogen-activated protein kinase 1	Homo sapiens	109-155
11449348-0	2001	Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.	murabutide	28-38	CCAAT enhancer binding protein beta	Homo sapiens	157-166
11449348-0	2001	Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.	murabutide	28-38	signal transducer and activator of transcription 1	Homo sapiens	171-176
11449348-0	2001	Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.	murabutide	28-38	CD14 molecule	Homo sapiens	186-190
11449348-0	2001	Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.	murabutide	28-38	toll like receptor 2	Homo sapiens	195-222
8282540-2	1993	Isotype specific suppression of peak hapten specific IgE antibody forming cell responses in BPO-KLH sensitized mice after oral administration of muramyldipeptide or murabutide.	murabutide	165-175	immunoglobulin heavy constant epsilon	Homo sapiens	53-56
8620558-5	1996	In contrast, treatment with MDP, murametide, or murabutide enhanced ICAM-1 (CD54) expression on monocyte and PMN cell surface in association with ICAM-1 mRNA synthesis.	murabutide	48-58	intercellular adhesion molecule 1	Homo sapiens	68-74
8620558-5	1996	In contrast, treatment with MDP, murametide, or murabutide enhanced ICAM-1 (CD54) expression on monocyte and PMN cell surface in association with ICAM-1 mRNA synthesis.	murabutide	48-58	intercellular adhesion molecule 1	Homo sapiens	76-80
8620558-5	1996	In contrast, treatment with MDP, murametide, or murabutide enhanced ICAM-1 (CD54) expression on monocyte and PMN cell surface in association with ICAM-1 mRNA synthesis.	murabutide	48-58	intercellular adhesion molecule 1	Homo sapiens	146-152
8894442-6	1996	Thus, in the presence of IL-2, IL-6, IL-3 or granulocyte-macrophage colony-stimulating factor (GM-CSF), the level of cytokines induced by murabutide was enhanced with no change in the other cytokines profile.	murabutide	138-148	interleukin 2	Homo sapiens	25-29
8894442-6	1996	Thus, in the presence of IL-2, IL-6, IL-3 or granulocyte-macrophage colony-stimulating factor (GM-CSF), the level of cytokines induced by murabutide was enhanced with no change in the other cytokines profile.	murabutide	138-148	interleukin 6	Homo sapiens	31-35
8894442-6	1996	Thus, in the presence of IL-2, IL-6, IL-3 or granulocyte-macrophage colony-stimulating factor (GM-CSF), the level of cytokines induced by murabutide was enhanced with no change in the other cytokines profile.	murabutide	138-148	interleukin 3	Homo sapiens	37-41
8894442-6	1996	Thus, in the presence of IL-2, IL-6, IL-3 or granulocyte-macrophage colony-stimulating factor (GM-CSF), the level of cytokines induced by murabutide was enhanced with no change in the other cytokines profile.	murabutide	138-148	colony stimulating factor 2	Homo sapiens	45-93
8894442-6	1996	Thus, in the presence of IL-2, IL-6, IL-3 or granulocyte-macrophage colony-stimulating factor (GM-CSF), the level of cytokines induced by murabutide was enhanced with no change in the other cytokines profile.	murabutide	138-148	colony stimulating factor 2	Homo sapiens	95-101
8894442-7	1996	IL-3 and GM-CSF were more potent in increasing the murabutide-induced response, eliciting synergistic effects on IL-8 and IL-1Ra production, at both the mRNA accumulation and the protein release.	murabutide	51-61	interleukin 3	Homo sapiens	0-4
8894442-7	1996	IL-3 and GM-CSF were more potent in increasing the murabutide-induced response, eliciting synergistic effects on IL-8 and IL-1Ra production, at both the mRNA accumulation and the protein release.	murabutide	51-61	colony stimulating factor 2	Homo sapiens	9-15
8894442-7	1996	IL-3 and GM-CSF were more potent in increasing the murabutide-induced response, eliciting synergistic effects on IL-8 and IL-1Ra production, at both the mRNA accumulation and the protein release.	murabutide	51-61	C-X-C motif chemokine ligand 8	Homo sapiens	113-117
8894442-7	1996	IL-3 and GM-CSF were more potent in increasing the murabutide-induced response, eliciting synergistic effects on IL-8 and IL-1Ra production, at both the mRNA accumulation and the protein release.	murabutide	51-61	interleukin 1 receptor antagonist	Homo sapiens	122-128
8796446-3	1996	One of these synthetic muramyl dipeptide (MDP) derivatives, namely murabutide which is in a clinical stage of development, has been recently found to synergize with IFN-alpha 2a in the selective induction of anti-inflammatory mediators and to enhance the biological activities of the therapeutic cytokine.	murabutide	67-77	interferon alpha 2	Homo sapiens	165-176
8742370-3	1996	We recently showed, in vitro and in vivo, a synergistic activity between the synthetic immunomodulator murabutide, which is in clinical stage of development, and another therapeutic cytokine, interferon-alpha (IFN-alpha).	murabutide	103-113	interferon alpha 1	Homo sapiens	210-219
8742370-4	1996	The present study was performed to assess a possible potentiation of the biologic activities of IL-2 by its association with murabutide.	murabutide	125-135	interleukin 2	Homo sapiens	96-100
8742370-5	1996	Human PBMC stimulated in vitro with IL-2 and murabutide showed synergistic levels of induced mRNA accumulation and protein secretion for IFN-gamma, IL-12, and colony-stimulating factors (CSFs).	murabutide	45-55	interferon gamma	Homo sapiens	137-146
8282540-3	1993	Muramyldipeptide (MDP) and murabutide (MB), a pyrogen free derivative of MDP, suppressed BPO specific IgE antibody forming cell (AFC) responses in vivo.	murabutide	27-37	immunoglobulin heavy constant epsilon	Homo sapiens	102-105
8282540-3	1993	Muramyldipeptide (MDP) and murabutide (MB), a pyrogen free derivative of MDP, suppressed BPO specific IgE antibody forming cell (AFC) responses in vivo.	murabutide	39-41	immunoglobulin heavy constant epsilon	Homo sapiens	102-105
33032082-7	2021	These novel DMPs were found to set off the release of higher levels of tumour necrosis factor alpha (TNF-alpha) than Murabutide, which is a well-known NOD2 agonist.	murabutide	117-127	nucleotide binding oligomerization domain containing 2	Homo sapiens	151-155
1565842-6	1992	Synthetic molecules (muramyl dipeptides) like MDP or murabutide (Mu), known as macrophage activators, were also efficient in inducing IL1 hyperexpression in sg/sg macrophages.	murabutide	53-63	interleukin 1 complex	Mus musculus	134-137
1565842-6	1992	Synthetic molecules (muramyl dipeptides) like MDP or murabutide (Mu), known as macrophage activators, were also efficient in inducing IL1 hyperexpression in sg/sg macrophages.	murabutide	65-67	interleukin 1 complex	Mus musculus	134-137
1707346-5	1991	After incubation with murabutide, a larger number of lymphocytes expressed Ta1 antigen (CD W26) and transferrin receptor (CD 71).	murabutide	22-32	transferrin receptor	Homo sapiens	75-120
1707346-5	1991	After incubation with murabutide, a larger number of lymphocytes expressed Ta1 antigen (CD W26) and transferrin receptor (CD 71).	murabutide	22-32	transferrin receptor	Homo sapiens	122-127
1707346-8	1991	Activation of polymorphonuclear cells by murabutide was confirmed by the up-regulation of the C3bi receptor, Fc receptor, and CD 14 surface antigen.	murabutide	41-51	CD14 molecule	Homo sapiens	126-131
2105274-7	1990	It was concluded that the enhancement induced by the adjuvants LPS, poly(A)-poly(U), and murabutide is mediated in part by their action on T cells resulting in release of IFN-gamma suggesting activation of a common transmembrane signal.	murabutide	89-99	interferon gamma	Homo sapiens	171-180
2463973-7	1988	Identical regulatory effects on IFN production were exerted by the adjuvant active analogue of MDP, namely murabutide.	murabutide	107-117	interferon alpha 1	Homo sapiens	32-35
2445212-4	1987	In the present report, we demonstrate that conjugates of the beta-subunit of hCG with muramyl dipeptide (MDP), or its nonpyrogenic derivative murabutide, may have potential as an effective antipregnancy vaccine.	murabutide	142-152	chorionic gonadotropin subunit beta 5	Homo sapiens	77-80
6332144-2	1984	MDP (muramyl dipeptide) and two of its structural analogs, murabutide and MDP-DD, were shown to inhibit the in vitro PHA-induced IL 2 production in a majority of normal individuals tested.	murabutide	59-69	interleukin 2	Homo sapiens	129-133
3527628-6	1986	MDP and its derivatives, such as murabutide, will also prove useful in combination with chemotherapy, especially for immunodepressed and elderly patients.	murabutide	33-43	dipeptidase 1	Homo sapiens	0-3
31054162-0	2019	NOD2 agonist murabutide alleviates radiation-induced injury through DNA damage response pathway mediated by ATR.	murabutide	13-23	nucleotide-binding oligomerization domain containing 2	Mus musculus	0-4
31054162-0	2019	NOD2 agonist murabutide alleviates radiation-induced injury through DNA damage response pathway mediated by ATR.	murabutide	13-23	ataxia telangiectasia and Rad3 related	Mus musculus	108-111
29688119-0	2019	Squalane-based emulsion vaccine delivery system: composition with murabutide activate Th1 response.	murabutide	66-76	negative elongation factor complex member C/D, Th1l	Mus musculus	86-89
29028529-5	2017	Furthermore, these compounds were able to trigger the secretion of higher levels of pro-inflammatory cytokine (TNF-alpha) than the well-studied NOD2 agonist, Murabutide.	murabutide	158-168	nucleotide binding oligomerization domain containing 2	Homo sapiens	144-148
29407676-7	2018	When murabutide was encapsulated within Ace-DEX MPs to test for controlled adjuvant delivery, fast-degrading MPs exhibited higher humoral and cellular responses in vivo at earlier time points, while slow-degrading MPs resulted in stronger responses at later time points.	murabutide	5-15	angiotensin I converting enzyme	Homo sapiens	40-43
23531213-4	2013	Murabutide is a safe derivative of MDP, which interacts with cells of the immune system, both innate and adaptive, and exerts its effect through activation of Nod2.	murabutide	0-10	nucleotide binding oligomerization domain containing 2	Homo sapiens	159-163
18008143-0	2008	Inhibition of apoptosis, activation of NKT cell and upregulation of CD40 and CD40L mediated by M. leprae antigen(s) combined with Murabutide and Trat peptide in leprosy patients.	murabutide	130-140	CD40 molecule	Homo sapiens	68-72
22855691-1	2012	Murabutide (MB) is a synthetic immunomodulator recognized by the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor on mammalian cells.	murabutide	0-10	nucleotide binding oligomerization domain containing 2	Homo sapiens	65-127
22855691-1	2012	Murabutide (MB) is a synthetic immunomodulator recognized by the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor on mammalian cells.	murabutide	0-10	nucleotide binding oligomerization domain containing 2	Homo sapiens	129-133
18008143-0	2008	Inhibition of apoptosis, activation of NKT cell and upregulation of CD40 and CD40L mediated by M. leprae antigen(s) combined with Murabutide and Trat peptide in leprosy patients.	murabutide	130-140	CD40 ligand	Homo sapiens	77-82
14687943-6	2004	Among the genes which were up-regulated by murabutide and with established effects on inhibiting virus transcription, was the octamer binding factor 1 (Oct-1).	murabutide	43-53	POU class 2 homeobox 1	Homo sapiens	126-150
14687943-6	2004	Among the genes which were up-regulated by murabutide and with established effects on inhibiting virus transcription, was the octamer binding factor 1 (Oct-1).	murabutide	43-53	POU class 2 homeobox 1	Homo sapiens	152-157
14687943-7	2004	We demonstrate the ability of murabutide to induce enhanced Oct-1 protein expression and DNA-binding activity in macrophages.	murabutide	30-40	POU class 2 homeobox 1	Homo sapiens	60-65
14975355-4	2004	In our previous study, the defective T cell function in LL patients was restored to a proliferating state with the release of TH1 type cytokines using mycobacterial antigen(s) with two immunomodulators (Murabutide (MDP-BE) and T cell epitope of Trat protein of Escherichia coli) by presenting the antigen in particulate form in vitro to PBMC derived from leprosy patients.	murabutide	203-213	negative elongation factor complex member C/D	Homo sapiens	126-129